Does DURVALUMAB Cause Immune-mediated myocarditis? 74 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 74 reports of Immune-mediated myocarditis have been filed in association with DURVALUMAB (IMFINZI). This represents 0.4% of all adverse event reports for DURVALUMAB.
74
Reports of Immune-mediated myocarditis with DURVALUMAB
0.4%
of all DURVALUMAB reports
29
Deaths
45
Hospitalizations
How Dangerous Is Immune-mediated myocarditis From DURVALUMAB?
Of the 74 reports, 29 (39.2%) resulted in death, 45 (60.8%) required hospitalization, and 25 (33.8%) were considered life-threatening.
Is Immune-mediated myocarditis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DURVALUMAB. However, 74 reports have been filed with the FAERS database.
What Other Side Effects Does DURVALUMAB Cause?
Death (2,817)
Malignant neoplasm progression (1,330)
Pneumonitis (827)
Radiation pneumonitis (786)
Pyrexia (573)
Diarrhoea (530)
Pneumonia (453)
Dyspnoea (444)
Interstitial lung disease (430)
Off label use (395)
What Other Drugs Cause Immune-mediated myocarditis?
PEMBROLIZUMAB (599)
NIVOLUMAB (444)
IPILIMUMAB (248)
CARBOPLATIN (93)
LENVATINIB (66)
DOXORUBICIN (59)
PACLITAXEL (58)
PEMETREXED (43)
ATEZOLIZUMAB (37)
BEVACIZUMAB (32)
Which DURVALUMAB Alternatives Have Lower Immune-mediated myocarditis Risk?
DURVALUMAB vs DUTASTERIDE
DURVALUMAB vs DUTASTERIDE\TAMSULOSIN
DURVALUMAB vs DUVELISIB
DURVALUMAB vs DYDROGESTERONE
DURVALUMAB vs EBASTINE